[摘要]目的 探討CIK細(xì)胞治療消化系統(tǒng)腫瘤的效果。方法 選取2012年1月1日～2014年2月25日我院收治的消化系統(tǒng)腫瘤患者100例為研究對(duì)象，按照消化系統(tǒng)腫瘤患者治療措施的差異分為對(duì)照組、實(shí)驗(yàn)組，每組50例。其中對(duì)照組實(shí)施姑息減癥治療，實(shí)驗(yàn)組則實(shí)施CIK細(xì)胞治療，對(duì)比兩組消化系統(tǒng)腫瘤患者治療結(jié)果的差異性。結(jié)果 實(shí)驗(yàn)組患者的CD3+與CD3+CD8+的水平顯著高于對(duì)照組（P<0.05）；兩組患者的OS與PFS比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。實(shí)驗(yàn)組患者的生活質(zhì)量顯著優(yōu)于對(duì)照組（P<0.05）；實(shí)驗(yàn)組患者的腫瘤標(biāo)志物（CA724、CA199）顯著低于對(duì)照組（P<0.05），兩組腹腔積液水平比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 消化系統(tǒng)腫瘤患者接受CIK細(xì)胞治療，可以對(duì)患者的免疫力、生活水平以及腫瘤標(biāo)志物進(jìn)行改善，但是在生存期、腹腔積液等方面無(wú)顯著的改善效果。
　　[關(guān)鍵詞]消化系統(tǒng)腫瘤；CIK細(xì)胞；生物治療
　　[中圖分類號(hào)] R735 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721（2018）2（b）-0086-03
　　CIK cells in the treatment of digestive system tumors
　　SUN Jie1 WANG Xing1 WANG Cui-fang1 ZHANG Chun-yang2
　　1.Department of Pathology，Affiliated Central Hospital of Shenyang Medical University，Liaoning Province，Shenyang 110024，China；2.Department of Emergency，Affiliated Central Hospital of Shenyang Medical University，Liaoning Province，Shenyang 110024，China
　　[Abstract]Objective To investigate the therapeutic effect of cik cells on digestive system tumors.Methods From January 1，2012 to February 25，2014，100 cases of digestive system tumor patients in our hospital were selected as the research objects，according to the differences in treatment measures of digestive system tumor patients were divided into control group，experimental group，50 cases in each group.The control group was treated with palliative treatment，while the experimental group was treated with CIK cells.The difference of treatment results between the two groups were compared.Results The levels of CD3+ and CD3+CD8+ in the experimental group were significantly higher than those in the control group （P<0.05）.There was no significant difference between the two groups in OS and PFS （P>0.05）.The quality of life of the experimental group was significantly better than that of the control group （P<0.05）.The tumor markers （CA 724，CA199） in the experimental group were significantly lower than those in the control group （P<0.05）.There was no significant difference in the level of peritoneal effusion between the two groups （P>0.05）.Conclusion Patients with digestive system tumors receiving CIK cell therapy can improve their immunity，living standards and tumor markers，but there is no significant improvement in survival time，peritoneal effusion and other aspects.
　　[Key words]Digestive system tumors；CIK cells；Biotherapy
　　消化系統(tǒng)腫瘤是惡性腫瘤之一，其具有較高的死亡率和發(fā)生率，其死亡率占據(jù)惡性腫瘤的首位[1]。隨著靶向治療、化療、放療、手術(shù)治療等綜合治療措施的應(yīng)用，使得消化道腫瘤患者的生存率得到了一定程度的提高。若消化系統(tǒng)腫瘤患者經(jīng)綜合治療后無(wú)效或處于疾病的晚期，則可為患者實(shí)施姑息治療[2-3]。隨著醫(yī)療技術(shù)水平的不斷發(fā)展，使得分子免疫技術(shù)和分子生物技術(shù)在不斷的發(fā)展，其中腫瘤生物治療具有特異性殺傷的效果，且毒副作用小，已經(jīng)逐漸被應(yīng)用于惡性腫瘤的治療中[4-5]。CIK（細(xì)胞因子誘導(dǎo)殺傷細(xì)胞）生物治療已經(jīng)在臨床中被廣泛的應(yīng)用。本文主要對(duì)消化系統(tǒng)腫瘤患者接受CIK細(xì)胞治療的價(jià)值作分析，現(xiàn)報(bào)道如下。

相關(guān)熱詞搜索：消化系統(tǒng) 腫瘤 細(xì)胞 效果 治療